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Background: Patients with proliferative lupus nephritis are at risk of frequent relapses. Whether low- dose prednisone
prevents relapses is uncertain.
Objectives: We undertook a pilot RCT to determine the feasibility of a larger trial.
Design: Pilot randomized controlled trial.
Setting: Single center Canadian outpatient nephrology clinic.
Patients: Participants with systemic lupus erythematosus (SLE) and a history of class III or IV lupus nephritis that
achieved at least partial remission and remained on prednisone were eligible.
Measurements: Feasibility: proportion of eligible patients randomized and adherence to tapering regimen. Clinical:
occurrence of renal or major non-renal flare of SLE.
Methods: We conducted a blinded, two-parallel-group randomized controlled trial of prednisone 7.5 mg/day
(continuation) compared to a matching placebo (withdrawal).
Results: Of nineteen eligible patients screened, 15 (79%) were recruited and randomized; 8 to prednisone continuation
and seven to withdrawal. All participants adhered to the tapering protocol to their assigned withdrawal or low-dose
maintenance target. Over 36 months, the primary outcome occurred in four (50%) patients in the continuation group
(three renal and one major non-renal flare), compared with one patient (14%) in the withdrawal group (one renal flare).
Three participants (38%) in the continuation group had minor flares, while no patients in the withdrawal group did.
Limitations: This pilot RCT was small and not designed to assess the efficacy or safety of maintenance with low-dose
prednisone.
Conclusions: The high proportion of eligible patients recruited, and success of protocol adherence suggest a large trial
of prednisone maintenance therapy compared to withdrawal is feasible.
Trial registration: Current Controlled Trials ISRCTN31327267.
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Contexte: Les patients atteints de néphropathie lupique proliférative sont sujets à de nombreuses rechutes. Il est
incertain que l’administration de faibles doses de prednisone aide à prévenir ses rechutes.
Objectifs: Nous avons entrepris un essai randomisé contrôlé (ERC) (étude pilote) afin de déterminer la faisabilité
d’une étude plus vaste.
Type d’étude: Essai randomisé contrôlé (étude pilote).
Contexte: La clinique externe de néphrologie d’un centre canadien.
Patients: Les personnes atteintes de lupus érythémateux disséminé (LED), avec antécédents de néphropathie
lupique de stades III et IV, en rémission (minimalement partielle) et toujours en traitement de maintien sous
prednisone étaient admissibles à l’étude.
Mesures: Faisabilité : Assignation aléatoire à partir de l’échantillon des patients admissibles et observance de la
posologie dégressive.
Clinique : apparition d’une poussée lupique rénale ou d’une poussée lupique grave non rénale.
Méthode: Nous avons mené un essai clinique aléatoire, en parallèle et à double insu, d’un groupe sous 7,5 mg de
prednisone (traitement continu) et d’un groupe sous placebo (sevrage).
Résultats: Du bassin des dix-neuf patients triés, 15 d’entre eux (79%) ont été sélectionnés. Le choix du traitement a
été attribué de façon aléatoire : 8 patients pour le traitement de maintien sous prednisone et 7 patients pour le
sevrage. Tous les participants ont observé le protocole de posologie dégressive qui leur était attribué et dont le but
était le sevrage ou le maintien avec de faibles doses de prednisone.
Sur une période de 36 mois, le premier indicateur des résultats est apparu chez quatre patients (50%) du groupe
sous prednisone à faible dose (trois poussées rénales et une poussée grave non rénale), comparativement à un
patient (14%) du groupe sous sevrage (une poussée rénale). Trois des participants (38%) du groupe sous
prednisone à faible dose ont eu des poussées lupiques mineures; aucune poussée lupique mineure n’est apparue
dans le groupe sous placebo.
Limites de l’étude: Cet essai randomisé contrôlé pilote a été effectué sur un petit groupe; il n’a pas été conçu
pour évaluer l’efficacité ou la sûreté d’un entretien sous prednisone à faible dose.
Conclusion: Le succès combiné du large échantillon de départ de patients admissibles et l’observance du
protocole de posologie dégressive laisse suggérer qu’une étude plus vaste comparant le traitement de maintien à
la prednisone et le sevrage est faisable.What was known before
The duration of prednisone use varies widely after remis-
sion is achieved in proliferative lupus nephritis (PLN).
Whether prednisone reduces the frequency of flares of
PLN is unclear.
What this adds
A randomized controlled trial comparing long-term low-
dose maintenance prednisone to placebo is likely feasible.
Background
Proliferative lupus nephritis (PLN; class III and IV lupus
nephritis) is a potentially organ and life threatening mani-
festation that affects up to 42% of patients with systemic
lupus erythematosus (SLE) [1]. Although over 80% of pa-
tients with PLN will initially respond to treatment, many
will have relapses that compromise quality of life, worsen
kidney function and can be life-threatening.
The prevention of disease relapse is typically accom-
plished with maintenance of remission therapy, such asimmunosuppressants, after remission is induced [2]. Al-
though glucocorticoids are used ubiquitously to induce re-
mission, their use to prevent relapses is heterogeneous and
there is very limited data from randomized controlled trials
(RCTs) to inform the issue [3,4].
Given the clinical equipoise surrounding the continu-
ation of low-dose glucocorticoids to prevent relapses of
SLE and PLN, a RCT is warranted. However, both pa-
tients and physicians often have strong opinions regard-
ing both the efficacy and safety of glucocorticoids which
can strongly influence a RCTs feasibility [5]. To assess the
feasibility of such a trial, we conducted a pilot RCT com-
paring prednisone 7.5 mg daily to a placebo.
Methods
We conducted a two-parallel-group randomized controlled
trial of prednisone 7.5 mg/day compared to a matching
placebo in a single center in Calgary, Canada. The objective
of this trial was to assess the feasibility of conducting a lar-
ger RCT that would determine the efficacy of long-term
Table 1 Example of rate of steroid taper for patients
allocated to the placebo arm and entering study on 15,
10 and 7.5 mg/day prednisone, respectively
Week Prednisone dose (mg/day)
1 15 10 7.5
2 15 10 7.5
3 10 7.5 5
4 10 7.5 5
5 7.5 5 4
6 7.5 5 4
7 5 4 3
8 5 4 3
9 4 3 2
10 4 3 2
11 3 2 1
12 3 2 1
13 2 1 0
14 2 1 0
15 1 0 0
16 1 0 0
17 0 0 0
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specific goals of this pilot RCT were to assess our ability to
recruit and randomize eligible participants, adherence to a
blinded taper and long-term use of a blinded study drug.
Patients were randomly allocated to either the prednis-
one or placebo group using a random number list gener-
ated by an independent statistician. Randomization was
blocked and stratified according to the duration of ster-
oid treatment at the time of enrollment (≤12 months or
>12 months) and remission status (partial or complete).
Allocation was concealed using sealed, opaque, se-
quentially numbered envelopes maintained by an inde-
pendent physician. When a participant was randomized,
the independent physician faxed the study number and
assigned treatment to the study pharmacy. Patients, in-
vestigators, care providers and data analysts remained
blinded to study treatment throughout the trial. The
University of Calgary research ethics board reviewed and
accepted the protocol and all participants provided writ-
ten informed consent.
Participants
Eligible patients were at least 18 years of age, had a his-
tory of SLE according to ACR criteria [6] and had either
class III or class IV lupus nephritis by the ISN/RPS clas-
sification system [7,8]. Patients who had class V lupus
nephritis in addition to class III or IV were also eligible.
Eligible patients must have had an index biopsy within
the three years previous to study enrolment, and could
have been induced with cyclophosphamide, mycopheno-
late or another immunosuppressant as seen as appropri-
ate by their physician. Patients were required to be in at
least partial remission at the time of randomization (de-
fined as having a) 0.3 to 2.9 g/day proteinuria, b) serum
albumin at least 30 g/L and c) stable renal function), be
receiving between 5 and 20 mg/day of prednisone and
provide informed consent. We excluded patients who
were pregnant, required prednisone for treatment of an-
other medical condition other than SLE, or were receiv-
ing or expected to receive renal replacement therapy
within the next six months.
Blinding
Blinding of prednisone was accomplished by over-
encapsulation of prednisone tablets. Over-encapsulation
allowed the groups to receive identical capsules while the
dose contained in the capsule for an individual could vary
between 1 and 10 mg. Placebo tablets and powder were
added to each capsule to ensure the weight of the capsules
were identical irrespective of the prednisone dose. Patients
presenting mild symptoms of prednisone withdrawal (mal-
aise, nausea, vomiting or hypotension not attributable to
another cause) had their prednisone dose increased to the
lowest dose achieved without symptom presentation andthen reattempted tapering at monthly intervals for a max-
imum of three attempts. Patients unsuccessful in tapering
maintained the lowest dose tolerated for the duration of
the trial. Blinding was maintained by instructing the phar-
macy to either proceed to the next step of the protocol
taper or the previous step of the taper without the study
physician knowing what dose was contained at each step.
Only the study pharmacy was aware of the actual doses
contained at each dose step for each patient. Conse-
quently, participants were unaware as to what dosage of




Patients in the prednisone withdrawal group tapered the
dose of prednisone contained in the capsules at a rate of
5 mg/day every two weeks until the dose was 10 mg/day,
then by 2.5 mg/day every two weeks until the dose was
5 mg/day and then by 1 mg/day every two weeks until
no prednisone and only placebo was contained in the
capsules (see Table 1 for complete tapering schedule). A
capsule containing placebo only was then continued for
the duration of the study.
Prednisone maintenance
Patients randomized to receive chronic, low-dose main-
tenance glucocorticoids were tapered from their steroid
dose at the time of randomization, if necessary, to a target
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nisone withdrawal group. Patients who were already on 5
to 7.5 mg/day of prednisone therapy were maintained on
their current dose with no changes made to the dose.
Other therapies
Immunosuppressive maintenance therapy was unchanged
during the study in the absence of a clinical reason. The
use of other therapies including hydroxychloroquine, anti-
hypertensives, non-steroidal anti-inflammatory drugs and
HMG CoA reductase inhibitors were left to the discretion
of the patients usual care providers. Vitamin D and cal-
cium were recommended for all patients in the trial as
osteoporosis prophylaxis. Any patient, regardless of group,
with a suspected or confirmed infection received stress
dose steroids by the attending physician, which we deemed
reasonable given the potential for symptoms of adrenal in-
sufficiency for prolonged periods after glucocorticoid with-
drawal [9,10].
Assessment and treatment of minor non-renal flares
Physicians were advised to treat minor flares (defined by
an increase in Systemic Lupus Erythematosus Activity
Index (SLEDAI) score of three points) with a two-week
course of 15 mg/day of prednisone. During the treat-
ment of minor flares physicians used open label prednis-
one. For patients experiencing a minor flare, if there was
no clinical response after two weeks of prednisone then
the patient had fulfilled the criteria for a major flare and
therefore met the pre-defined primary study endpoint.
Outcomes
Patients were followed for up to 36 months. The feasibil-
ity of a larger study was assessed by calculating the pro-
portion of patients screened that were eligible and the
proportion of eligible patients that agreed to participate
and were randomized. Feasibility was also assessed by
evaluating adherence to the blinded tapering protocol by
calculating the proportion of participants with at least
one protocol deviation.
The primary clinical outcome measure was the compos-
ite of renal or major non- renal SLE relapse. A renal re-
lapse was defined as one of any of three events attributed
to active SLE (see Appendix 1 for details) 1) a sustained
and significant increase in proteinuria; 2) a sustained in-
crease in serum creatinine with new hematuria; or 3) new
and sustained glomerular hematuria associated with an in-
crease in proteinuria. A major non-renal flare was defined
as either 1) a score greater than nine on the Systemic
Lupus Erythematosus Activity Index (SLEDAI) for pa-
tients with a baseline score greater than three or, 2) new
or worse CNS vasculitis, myositis, platelet count <60,000/
mL, anemia with hemoglobin <70 g/L or requirement of
prednisone dose >15 mg/day or, 3) hospitalization for SLEor, 4) requirement for new or increased immunosuppres-
sant agent due to disease activity.
Secondary outcome measures included change in
health related quality of life measured with the SF-36 en-
ergy domain (chosen a priori given that this domain of
quality of life might be impacted by withdrawal of pred-
nisone and lupus flares), and the EQ5D index score
[11,12]. Exploratory outcome measures included the fre-
quency of adverse events, minor relapses of SLE (i.e. re-
lapses that did not meet the definition of a major
relapse) and change in blood pressure over the first12
months.Statistical analyses
Feasibility assessment was conducted by calculating the
proportion of patients enrolled from the total eligible pa-
tients and reported as a frequency (%), protocol viola-
tions were calculated and reported in the same way.
Baseline patient characteristics are reported as frequency
(%) and mean (SD) or median (25th to 75th percentile) as
appropriate. For the primary analysis, we compared the
time to renal or major non-renal relapse using Cox pro-
portional hazard regression with treatment group as the
only independent variable. Analysis time was censored
at the time of last follow-up or the occurrence of the
primary outcome. The time to first renal or major non-
renal relapse was graphically represented with the
Kaplan-Meier product limit method. Between group dif-
ferences in renal and major non-renal relapses, as well
as adverse events were assessed using cox regression in
which the allocated treatment was the only independent
variable. Mixed effects linear regression was used to as-
sess between group differences in SF-36 energy domain,
EQ5D index score, and blood pressure to account for
repeated measures over time. In these analyses, partici-
pants were considered a random effect and treatment
group was considered a fixed effect. All analyses were
completed with STATA 13 (College Station, Texas,
USA).Results
We screened fifty-five patients over a 24 month period, of
which 19 (34.5%) met eligibility criteria. The largest num-
ber of screening failures were either because patients were
no longer receiving prednisone (14/36 [39%]) or they were
receiving too high a dose (5/36 [14%]). Of the eligible pa-
tients, 15 (79%) were enrolled in the study (Figure 1).
Eight patients were allocated to prednisone continuation
and seven were allocated to prednisone withdrawal. Table 2
summarizes the participant baseline characteristics. The
groups differed in mean age and the proportion of patients
in complete remission at randomization. The remainder
of the characteristics appeared broadly similar.
Figure 1 Participant flow chart.
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group, moved away from the study center within the
first month, and follow-up data was not available for
this patient (Figure 1). Two patients left the study to
become pregnant, at 6 months and 18 months. No proto-
col violations occurred during the tapering regimen. All
participants were successfully tapered to their assigned
withdrawal or low-dose maintenance target, though one
patient in the prednisone continuation group experienced
symptoms that were felt to be consistent with prednisone
withdrawal. Patients were followed for a median of
11.9 months with a total follow-up of 20.7 person-years.Relapses
Four patients (50%) in the continuation group experienced
the primary outcome (three renal flares occurring at 182,
190 and 358 days, and one major non-renal flare at
127 days), compared with one event (14%) (renal flare at
98 days) in the withdrawal group (hazard ratio (HR) 2.68,
95% CI 0.28 to 25.8) (Table 3 and Figure 2). Three partici-
pants (38%) had minor flares in the prednisone continu-
ation arm, occurring at 91, 119, and 175 days (including
one that progressed to a major non-renal flare, and one
that progressed to a renal flare later on), while no patientsin the prednisone withdrawal arm experienced minor
flares (Table 3).Other outcomes
There was no significant difference in SF-36 energy scores
between the continuation group and the withdrawal group
(9.42, 95% CI 4.53 to 19.59). There was also no apparent
difference in the change in EQ5D index scores between
the continuation group and the withdrawal group (0.67,
95% CI 0.01 to 0.53). Finally, a mixed effects regression
analysis for systolic blood pressure, for each patient across
all time intervals, found no significant difference compar-
ing the continuation and withdrawal groups (11.54, 95%
CI 7.58 to 17.51).
Four participants (50%) in the prednisone continuation
group experienced adverse events compared with two
(29%) in the prednisone withdrawal group (HR 1.13,
95% CI 0.18 to 6.93). One participant in the prednisone
continuation group had two separate episodes of frac-
ture, while two patients developed infections, including
one urinary tract infection (Table 4). In the prednisone
withdrawal group, one patient had three separate urinary
tract infections, and one patient had two separate events
of gout and eczema. No patients developed diabetes, and
Table 2 Participant characteristics at randomization
Overall Prednisone continuation Prednisone withdrawal
(n=15) (n=8) (n=7)
Age (yr), mean (sd) 34.2 (11.2) 39.2 (12.8) 28.4 (5.6)
Female gender, n (%) 13 (86.7) 6 (75) 7 (100)
On steroids >12 months, n (%) 10 (77) 7 (88) 3 (60)
Duration from biopsy to enrollment (days),
median (25th to 75th percentile)
342 (463) 495 (497) 331 (548)
Serum creatinine (umol/L), mean (sd) 82.9 (45.4) 85.9 (34.5) 79.4 (58.4)
Proteinuria (g/mmol), mean (sd) 0.07 (0.07) 0.06 (0.07) 0.09 (0.07)
Hemoglobin A1c (%), mean (sd) 5.08 (0.62) 4.8 (0.87) 5.3 (0.2)
Blood Pressure, mmHg (sd)
Systolic 118.3 (16.3) 125.5 (18.1) 110 (9.4)
Diastolic 73.1 (10.4) 76.3 (10.7) 69.4 (9.5)
Renal Biopsy Class, n (%)a
III 4 (29) 3 (43) 1 (14)
IV 10 (71) 4 (57) 6 (86)
V 8 (57) 3 (43) 5 (71)
Complete remissionb, n (%) 9 (60) 7 (88) 2 (29)
SLEDAI total scorec, mean (sd) 1.3 (2.9) 0.25 (0.7) 2.57 (3.9)
SLICC/ACR indexd, mean (sd) 0.5 (0.9) 0.75 (1.2) 0.29 (0.5)
Prednisone dose (mg/day), mean (sd) 8.1 (1.9) 8.8 (1.6) 7.5 (2.04)
Baseline Cytotoxic Use
Cyclophosphamide, n (%) 0 0 0
Mycophenolate, n (%) 9 (60) 4 (50) 5 (71)
Azathioprine, n (%) 4 (27) 3 (38) 1 (14)
None, n (%) 2 (13) 1 (12.5) 1 (14)
aISN/RPS International Society of Nephrology/Renal Pathology Society.
bComplete remission was defined as having a) less than 0.3 g/day proteinuria, b) normal urine sediment, c) normal serum albumin concentration and d) creatinine
value less than 15% above baseline. Partial remission was defined as having a) 0.3 to 2.9 g/day proteinuria, b) serum albumin at least 30 g/L and c) stable
renal function.
cSLEDAI, Systemic Lupus Erythematosus Activity Index.
dSLICC/ACR, Systemic Lupus International Collaborative Clinics/American College of Rheumatology.
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symptoms consistent with prednisone withdrawal.
Discussion
In this pilot randomized controlled trial of patients with










3 (38) 1 (14) 2.68 (0.28, 25.8)
All flares,
n (%)
4 (50) 1 (14) 3.35 (0.37, 30.1)
Minor
flares, n (%)
3 (38) 0 (0) a
aHazard ratio could not be computed.we were able to randomize 79% of eligible patients to
withdrawal or continuation of low dose corticosteroids.
Given the absence of protocol violations, and adherence
to the blinded tapering of prednisone, it is feasible to
conduct a large placebo controlled study to determine
the efficacy and safety of low-dose prednisone in PLN
with this protocol.
To our knowledge, this is the first trial comparing
prednisone withdrawal and low-dose prednisone main-
tenance of remission therapy in patients with a history
of PLN. RCTs in rheumatoid arthritis suggests low-dose
prednisone modifies disease activity with few side-effects
[13]. Early prednisone withdrawal in renal transplant-
ation is associated with more episodes of rejection and
in systemic vasculitis early withdrawal is associated with
more frequent relapses of disease [14,15]. Finally, small
RCTs in SLE suggest moderate doses of prophylactic
prednisone attenuate the risk of relapse in patients with
Figure 2 Survival analysis for renal and non-renal flares.
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ever, enthusiasm for long-term prednisone, even if ef-
fective, is tempered by potential side-effects such as
infection, gastrointestinal bleeding, and fractures [16].
Together, these data along with substantial practice pat-
tern variation suggest a RCT of long-term low-dose glu-
cocorticoids is warranted.
The main purpose of this pilot trial was to inform the
design and conduct of a larger trial that would assess the
efficacy and safety of long-term low-dose prednisone in
patients with PLN. Such a trial is estimated to require at
least 334 patients to detect a 50% reduction in the com-
posite outcome of renal or major non-renal relapse of SLE
with 90% power with an average of four years follow-up.
Based on our screening and recruitment results, we would
require at least 23 similar centers to finish recruitment in
2 years without substantial change to the eligibility criteria.
To detect a smaller effect of prednisone much larger sam-





Overall, n (%) 4 (50) 2 (29)
Fracture 1a 0
Infection 2 2b




aOne patient had both a wrist and foot fracture, independently.
bOne patient had three separate incidents of UTI.at least 1700 patients). As such, a large trial to answer this
question would almost certainly need to be international
in scope. However, given how ubiquitously glucocorticoids
are used and how important remission maintenance is,
such a trial is warranted. The importance of this is under-
scored by the relative lack of efficacy of many newer adju-
vant agents in preventing lupus flares [17,18].
Our pilot RCT has several strengths. We were able to
blind both patients and physicians to the withdrawal of
prednisone. This improved the objectivity of disease as-
sessment, an inherently subjective process that may be af-
fected by patients and physicians strong underlying beliefs
regarding the efficacy of glucocorticoids. We enrolled a
broad sample of participants some of which were on very
long-term glucocorticoids. This demonstrated that it is
possible to withdraw glucocorticoids in these patients in a
safe manner and improves the generalizability of the study
procedures.
The results of this pilot should be interpreted in light
of the study limitations. Our pilot RCT was of insuffi-
cient size to assess the efficacy or safety of long-term
low-dose prednisone. Even were statistically significant
differences in the risk of relapse or adverse events noted
in our trial, they would very likely be chance findings
[19]. This was a single center experience which limits
our confidence that the protocol could be generalized to
other centers for a large RCT. However, the process of
conducting the pilot informs the design of a larger trial
and we believe that such a trial could be further simpli-
fied to ensure its feasibility. Also, we chose a dose of
7.5 mg per day of prednisone as our low- dose target. It
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ficacy and safety and different dosing may also alter the
feasibility of the trial. However, there is little data to
guide an optimal dose and prednisone 7.5 mg daily rep-
resents a commonly low-dose threshold.
Conclusions
This pilot RCT demonstrated the feasibility of the study
protocol. A larger trial comparing prednisone withdrawal
and low-dose prednisone as maintenance therapy is pos-
sible and is warranted. Any such trial must carefully con-
sider the limited number of patients at each site, as well as
individual patients’ complex treatment regimens in that
trial’s eligibility criteria and the consideration of the out-
come of relapse.
Appendix 1 Renal flare definition
A renal flare was defined as the occurrence of any one
of the three following events:
1. Increased proteinuria, measured by either 24 hour
urine collection or by a urine protein to creatinine ratio,
by at least a) 1 g/day if the baseline proteinuria was less
than 0.2 g/day or, b) 2 g/day if the baseline proteinuria
was between 0.2 and 1 g/day (inclusive), or c) more than
double the baseline proteinuria if the baseline protein-
uria was greater than 1 g/day [20].
2. A sustained (i.e. for two consecutive measures) in-
crease in serum creatinine by at least 30% over baseline
that was not due to institution of antihypertensive ther-
apy or angiotensin converting enzyme inhibitor therapy
and with new hematuria attributable to active SLE.
3.New sustained hematuria attributable to active SLE,
and exclusive of menses, infection or medications, that
was associated with an increase in proteinuria by at least
0.8 g/day.
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